Document Detail

Development of integrase inhibitors of quinolone acid derivatives for treatment of AIDS: an overview.
MedLine Citation:
PMID:  21044030     Owner:  NLM     Status:  In-Process    
HIV-1 integrase (IN), which has no cellular counterpart, has been intensely studied over the past 15 years and has been fully validated as a therapeutic target with the first FDA approved IN inhibitor raltegravir. The quinolone acid GS-9137 (elvitegravir), which most probably will became the next candidate of IN inhibitors, is in the process of enrolling patients in the phase III clinical trials. This review focuses on small-molecules of quinolone acid derivatives, which have the similar pharmacophore of β-diketoacids, as integrase inhibitors with antiviral activity.
Z G Luo; J J Tan; Y Zeng; C X Wang; L M Hu
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Mini reviews in medicinal chemistry     Volume:  10     ISSN:  1875-5607     ISO Abbreviation:  Mini Rev Med Chem     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-11-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101094212     Medline TA:  Mini Rev Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1046-57     Citation Subset:  IM    
College of Life Science and Bioengineering, Beijing University of Technology, Beijing 100124, P. R. China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An update on venous thromboembolism in trauma, orthopaedic and reconstructive surgery.
Next Document:  Parallel artificial membrane permeability assay (PAMPA) - Is it better than Caco-2 for human passive...